

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## FRONTAGE HOLDINGS CORPORATION

方達控股公司\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1521)**

### UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This announcement is made by Frontage Holdings Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors of the Company (the “**Board**”) has noted a decrease in the price and an increase in the trading volume of the shares of the Company on the Stock Exchange on 26 January 2024. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reasons for these price movements or of any information which must be announced to avoid a false market in the Company’s shares or of any inside information which needs to be disclosed under Part XIVA of the Securities and Futures Ordinance.

The Board wishes to inform its shareholders and potential investors that on 26 January 2024, certain directors and employees of the Company, including the non-executive director, Dr. Zhihe Li, and the chief executive officer of the Company, Dr. Abdul Mutlib, exercised certain share options (the “**Relevant Options**”) granted to them under the Pre-IPO share incentive plan adopted by Frontage Laboratories, Inc. in 2015 and assumed by the Company on April 17, 2018, and disposed of a total of 10,656,923 shares of the Company allotted and issued to them pursuant to such exercise on the same day. The exercise price of the Relevant Options was US\$0.20 per share. The Relevant Options would expire on 28 February 2024 if they were not exercised before that date. Dr. Zhihe Li and Dr. Abdul Mutlib are prohibited from dealing in the shares of the Company from 28 January 2024 until the publication of the Company’s 2023 annual results announcement, which is currently expected to be made on 28 March 2024, pursuant to the Company’s policy regarding dealings in the Company’s shares by directors and employees.

In addition, on 26 January 2024, a total of 1,620,741 shares have been disposed of by grantees of certain restricted share units granted under the Company’s 2021 Share Award Scheme after they vested on 25 January 2024.

This announcement is made by the order of the Company. The Company’s Board of Directors collectively and individually accepts responsibility for the accuracy of this announcement.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Frontage Holdings Corporation**  
**Dr. Song Li**  
*Chairman*

Hong Kong, 26 January 2024

*As at the date of this announcement, the Board comprises Dr. Song Li as executive director; Dr. Zhihe Li, Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.*

\* *For identification purposes only*